Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2019-08-28 Board/Management Inform…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a formal company announcement regarding the appointment of a new Chief Financial Officer (Matthew Dallas) at Zealand Pharma A/S. It details the executive's background, the effective date of the appointment, and the transition from the interim CFO. This falls squarely under the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2019-08-28 English
Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer
Board/Management Information Classification · 98% confidence The document is a formal announcement from Zealand Pharma A/S, titled 'Company announcement – No. 27 / 2019', detailing the appointment of a new Chief Financial Officer (Matthew Dallas). This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' Although it is a regulatory announcement, the specific content points directly to MANG rather than the general RNS fallback. The document length is short (4360 chars) and it announces an event/change, not the release of a comprehensive report.
2019-08-28 English
Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a formal company announcement regarding the appointment of a new Chief Financial Officer (Matthew Dallas) at Zealand Pharma. This falls directly under the category of management changes, which is defined as 'Board/Management Information'.
2019-08-28 English
Board/Management Information 2019
Board/Management Information Classification · 100% confidence The document is a formal company announcement (Company announcement – No. 27 / 2019) detailing the appointment of a new senior executive, Matthew Dallas, as Chief Financial Officer. This type of announcement, concerning changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information'. Therefore, the appropriate filing code is MANG.
2019-08-28 English
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 98% confidence The document is an official company announcement regarding an increase in share capital resulting from the exercise of employee warrants. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction (number of shares, price, total proceeds, and impact on total share capital), making it a primary announcement of a capital change rather than just a report publication announcement.
2019-08-23 English
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 98% confidence The document is an official company announcement regarding an increase in share capital resulting from the exercise of employee warrants. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction (number of shares, price, total proceeds, and impact on total share capital), making it a primary announcement of a capital change rather than just a report publication announcement.
2019-08-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.